Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670590 | 0.90 | CNR2 (0.35) | CNR2CNR1TSHRALDH1A1 | |
| SCHEMBL469313 | 0.83 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL14647262 | 0.82 | CNR2 (0.33) | CNR2 | |
| SCHEMBL1621233 | 0.82 | CNR2 (0.31) | CNR2TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL1621074 | 0.80 | EPHX1 (0.32) | CNR2 | |
| SCHEMBL351268 | 0.79 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL14664306 | 0.79 | CNR2 (0.32) | CNR2 | |
| SCHEMBL10171735 | 0.78 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL2184860 | 0.78 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL766807 | 0.78 | CNR2 (0.32) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344601-B2 | (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240092769-A1 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220135554-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
| US-20220135554-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
| US-11084810-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084810-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200262830-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2020-08-20 | — | — | US | disclosed |
| WO-2010036630-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036631-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036631-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039645-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885TSHR 971/4885 |
| US-20200262830-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TSHR 759/4885 |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TSHR 945/4885 |
| US-20240092769-A1 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TSHR 945/4885 |
| US-11084810-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TSHR 945/4885 |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885TSHR 843/4885 |
| US-20220135554-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TSHR 759/4885 |
| US-12344601-B2 | (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TSHR 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.